Rituximab in Patients with the Steroid-Resistant Nephrotic Syndrome
Authors:
- Arvind BaggaABArvind Bagga
- Aditi SinhaASAditi Sinha
- Asha MoudgilAMAsha Moudgil
- 28 June 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (26) , 2751-2752
Abstract
The treatment of patients with the steroid-resistant nephrotic syndrome (SRNS) is challenging. Persistent proteinuria and hypoalbuminemia result in serious complications and progressive kidney disease. Intensive treatment regimens show varying results in inducing remission but are associated with adverse effects. On the basis of suggestions that B lymphocytes are crucial in the pathogenesis of the nephrotic syndrome,1 we examined the efficacy of treatment with rituximab, a monoclonal antibody against CD20 antigen, in patients with SRNS that was resistant to treatment with high-dose corticosteroids, alkylating agents, and calcineurin inhibitors.Keywords
This publication has 5 references indexed in Scilit:
- Unexpected Efficacy of Rituximab in Multirelapsing Minimal Change Nephrotic Syndrome in the Adult: First Case Report and Pathophysiological ConsiderationsAmerican Journal of Kidney Diseases, 2007
- Rituximab therapy for steroid-dependent minimal change nephrotic syndromePediatric Nephrology, 2006
- Resolution of Recurrent Focal Segmental Glomerulosclerosis Proteinuria after Rituximab TreatmentNew England Journal of Medicine, 2006
- Change of the course of steroid-dependent nephrotic syndrome after rituximab therapyPediatric Nephrology, 2004
- Recent approaches to the pathogenesis of minimal-change nephrotic syndromeNephrology Dialysis Transplantation, 2003